Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Andrés J. Muñoz, Laura Ortega, Ana Gutiérrez, Enrique Gallardo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Blanca Morón, Pilar García-Alfonso & José Manuel Soria. (2023) Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain. Journal of Medical Economics 26:1, pages 1145-1154.
Read now
Read now
J Aguilar-Serra, V Gimeno-Ballester, a Pastor-Clerigues, J Milara, C Trigo-Vicente & J Cortijo. (2022) Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 637-646.
Read now
Read now
Francesc Formiga, Pablo García-Pavía, Francisco Javier Martín Sánchez, Andrés Navarro-Ruiz, Carlos Rubio-Terrés, Carmen Peral, Patricia Tarilonte, Alejandra López-Ibáñez de Aldecoa & Darío Rubio-Rodríguez. (2021) Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 1127-1133.
Read now
Read now
Hae Kyung Kim, Carmen Peral, Darío Rubio-Rodríguez & Carlos Rubio-Terrés. (2021) Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 315-320.
Read now
Read now
Pablo Irimia, Sonia Santos-Lasaosa, Laura García Bujalance, Luis Ramos Pinazo, Darío Rubio-Rodríguez & Carlos Rubio-Terrés. (2021) Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 285-297.
Read now
Read now
Malabika Sen, Audrey Kindsfather, Ludmila Danilova, Feng Zhang, Raffaele Colombo, Matthew G. LaPorte, Brenda F. Kurland, Donna M. Huryn, Peter Wipf & James G. Herman. (2020) PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. Epigenetics 15:6-7, pages 604-617.
Read now
Read now
Carl Samuelsen, Jonathan Lim, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch. (2020) Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. Journal of Medical Economics 23:1, pages 48-53.
Read now
Read now
Articles from other publishers (10)
Ricardo Ginestal, Carlos Rubio-Terrés, Olga Durán Morán, Darío Rubio-Rodríguez, Heidi De Los Santos, Cristina Ordoñez & Isabel Sánchez-Magro. (2023) Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. Journal of Comparative Effectiveness Research 12:2.
Crossref
Crossref
Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, Inmaculada Jarrín, Antonio Castro, Darío Rubio-Rodríguez & Carlos Rubio-Terrés. (2022) Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?. Enfermedades infecciosas y microbiologia clinica (English ed.) 40:10, pages 550-556.
Crossref
Crossref
Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, Inmaculada Jarrín, Antonio Castro, Darío Rubio-Rodríguez & Carlos Rubio-Terrés. (2022) Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?. Enfermedades Infecciosas y Microbiología Clínica 40:10, pages 550-556.
Crossref
Crossref
Carlota Moya-Alarcón, Almudena González-Domínguez, Yoana Ivanova-Markova, Vicente Gimeno-Ballester, Maria-Pilar Barretina-Ginesta, José Alejandro Pérez-Fidalgo & Andrés Redondo. (2022) Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. Gynecologic Oncology 164:2, pages 406-414.
Crossref
Crossref
Javier Aguilar-Serra, Vicente Gimeno-Ballester, Alfonso Pastor-Clerigues, Javier Milara, Ezequiel Marti-Bonmati, Cristina Trigo-Vicente & Julio Cortijo. (2021) Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis. Journal of Comparative Effectiveness Research 10:4, pages 325-335.
Crossref
Crossref
Carlos Rubio-Terrés, José María Aguado, Benito Almirante, Javier Cobo, Santiago Grau, Miguel Salavert, Elena González Antona Sánchez, Cristina López Gutiérrez & Darío Rubio-Rodríguez. (2019) Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. European Journal of Clinical Microbiology & Infectious Diseases 38:6, pages 1105-1111.
Crossref
Crossref
Ibiayi Dagogo-JackChristopher G. AzzolliFlorian FintelmannMari Mino-KenudsonAnna F. FaragoJustin F. GainorGinger JiangZofia PiotrowskaRebecca S. HeistInga T. LennesJennifer S. TemelMeghan J. MooradianJessica J. LinSubba R. DigumarthyJulie M. BattenHayley RobinsonVania NoseMiguel RiveraValentina NardiDora Dias-SantagataLong P. LeLecia V. SequistMartha PitmanJo-Anne O. ShepardAlice T. ShawA. John IafrateJochen K. Lennerz. (2018)
Clinical Utility of Rapid
EGFR
Genotyping in Advanced Lung Cancer
. JCO Precision Oncology:2, pages 1-13.
Crossref
Crossref
Adolfo Favaretto, Francesco Grossi, Alessandro Morabito & Roberto Ravasio. (2017) Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 4:1, pages grhta.5000270.
Crossref
Crossref
. (2017) Erlotinib reduces AE rate and healthcare costs versus afatinib. Reactions Weekly 1635:1, pages 9-9.
Crossref
Crossref
. (2017) Erlotinib reduces AE rate and healthcare costs versus afatinib. PharmacoEconomics & Outcomes News 770:1, pages 13-13.
Crossref
Crossref